TNFRSF5/CD40

TNFRSF5/CD40 Related Products (34):

By Type:	Pan (15) Selective (9)
By Effects:	Inhibitors (29) Agonist (1) Antagonist (1) Activator (1) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-110203

R-7050	Antagonist	99.96%
R-7050 (TNF-α Antagonist III) is a tumor necrosis factor receptor (TNFR) antagonist with greater selectivity toward TNFα.

HY-134471

TNF-α-IN-2	Inhibitor	98.75%
TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα), with an IC₅₀ of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1. TNF-α-IN-2 can be used for the research of rheumatoid arthritis.

HY-122663A

BIO8898	Inhibitor	99.88%
BIO8898 is a potent CD40-CD154 inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC₅₀ value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis.

HY-P99111

Golimumab	Inhibitor	99.71%
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.

HY-147045

UCB-5307	Inhibitor
UCB-5307 is a potent TNF signaling inhibitor with a K_D of 9 nM for human TNFα. UCB-5307 can penetrate the preformed hTNF/hTNFR1 complex.

HY-P3483

Maxadilan	Inhibitor
Maxadilan is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan exhibits anti-apoptotic activity in hADSCs. Maxadilan inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10). Maxadilan can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan promotes neural differentiation of human adipose-derived stem cells. Maxadilan can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases^{[1][2][3][4][5]}.

HY-P991556

TQB2916	Agonist
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research.

HY-174825

TRPM8 antagonist 4	Inhibitor
TRPM8 antagonist 4 is a CB2R partial agonist (EC₅₀=54.2 nM, K_i=3.2 μM) and TRPM8 antagonists (IC₅₀=42.3 nM) with high functional selectivity and good physicochemical properties. TRPM8 antagonist 4 has significant anti-inflammatory and analgesic effects and good safety, reduces the mRNA expression of TNF-α, IL-6, and IL-1β.

HY-P99670

Iscalimab	Inhibitor	99.64%
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.

HY-P99742

Mitazalimab	Inhibitor	99.23%
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

HY-P99325

Toralizumab	Inhibitor	99.57%
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease.

HY-P99167

Lucatumumab	Inhibitor	98.18%
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.

HY-118250

GSK2245035	Activator	99.85%
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC₅₀s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma.

HY-154822

DRI-C25441	Inhibitor	99.53%
DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC₅₀ of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen.

HY-115620

AQX-016A	Inhibitor	98.00%
AQX-016A is an orally active and potent SHIP1 agonist. AQX-016A can activate recombinant SHIP1 enzyme in vitro and stimulate SHIP1 activity. AQX-016A also can inhibit the PI3K pathway and TNFa production, can be useful for various inflammatory diseases research.

HY-P99701

Letolizumab	Inhibitor
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.

HY-147078

EJMC-1	Inhibitor	99.69%
EJMC-1 is a moderately potent TNF-α inhibitor with an IC₅₀ value of 42 μM.

HY-P99821

Ravagalimab	Inhibitor	99.31%
Ravagalimab (ABBV-323) is a CD40 antagonist (EC₅₀: 3.7 nM). Ravagalimab can be used for research of Crohn's disease.

HY-P99572

Tecaginlimab	Inhibitor	99.00%
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity.

HY-154821

DRI-C21041	Inhibitor
DRI-C21041 is a CD40/CD40L interaction inhibitor, with an IC₅₀ of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen.

Name
Email *

	Sorry, but the email address you supplied was invalid.